Novo Nordisk Shares Plunge as Key Drug Trial Misses Target Against Lilly
Novo Nordisk’s stock tumbled 15% Monday, reaching its lowest point since mid-2021, after the company disclosed that its experimental weight-loss drug CagriSema failed to prove it was at least as...